1. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Presentación del ESC Congress 2022
Scott D Salomon e al. N Engl J Med. 2022
Doi: 10.1056/NEJMoa2206286
DELIVER Trial
Dapagliflozin Evaluation to improve the LIVEs of patients with
PReserved Ejection Fraction Heart Failure
DELIVER

2. Martina Amiguet Comins
DELIVER Trial
Espacio reservado para
la imagen del ponente
Background & Objectives Inclusion criteria & study design Study population Results Conclusions
Presentación del ESC Congress 2022
Scott D Salomon e al. N Engl J Med. 2022
Doi: 10.1056/NEJMoa2206286
ENDPOINTS
PRIMARY ENDPOINT
Time to first occurrence of any of the components of
the composite CV death + HF hospitalization + Urgent
HF visit
SECONDARY ENDPOINTS
• Change from baseline in the total symptom score of
KCCQ at 8 months
• Total number of HF events
• Time to the ocurrence of CV death
• Time to the ocurrence of death from any cause
SAFETY ENDPOINT
Serious AEs, AEs leading to treatment discontinuation,
amputations, AEs leading to amputation and potential risk factor
fro AEs leading to amputqations affecting the lower limbs.
SGLT2i have shown benefit in CVD, HFrEF and CKD, regardless of diabetes status.
HFpEF is an heterogeneous entity with modest benefit of prognosis drugs until the publication of EMPEOR preserved.
Full population
LVEF<60%
DELIVER Study Design
Salomon et al Eur J Heart Fail 2021

3. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Background & Objectives Study population Results Conclusions
Presentación del ESC Congress 2022
Scott D Salomon e al. N Engl J Med. 2022
Doi: 10.1056/NEJMoa2206286
Inclusion criteria & study design
DELIVER Trial
DELIVER Study Design
Salomon et al Eur J Heart Fail 2021

4. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Study population Results Conclusions
Presentación del ESC Congress 2022
Scott D Salomon e al. N Engl J Med. 2022
Doi: 10.1056/NEJMoa2206286
Background & Objectives Inclusion criteria & study design
DELIVER Trial
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction
https://doi.org/10.1016/j.jchf.2021.11.006

5. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Study population Results Conclusions
Presentación del ESC Congress 2022
Scott D Salomon e al. N Engl J Med. 2022
Doi: 10.1056/NEJMoa2206286
Background & Objectives Inclusion criteria & study design
DELIVER Trial
18%
NNT=32

6. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Study population Results Conclusions
Presentación del ESC Congress 2022
Scott D Salomon e al. N Engl J Med. 2022
Doi: 10.1056/NEJMoa2206286
Background & Objectives Inclusion criteria & study design
DELIVER Trial

7. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Study population Results Conclusions
Presentación del ESC Congress 2022
Scott D Salomon e al. N Engl J Med. 2022
Doi: 10.1056/NEJMoa2206286
Background & Objectives Inclusion criteria & study design
DELIVER Trial
Consistency is observed in the previously specified subgroups

8. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Study population Results Conclusions
Presentación del ESC Congress 2022
Scott D Salomon e al. N Engl J Med. 2022
Doi: 10.1056/NEJMoa2206286
Background & Objectives Inclusion criteria & study design
DELIVER Trial
Serious adverse events leading to discontinuation were similar between dapaglifozin and placebo

9. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Study population Results Conclusions
Presentación del ESC Congress 2022
Scott D Salomon e al. N Engl J Med. 2022
Doi: 10.1056/NEJMoa2206286
Background & Objectives Inclusion criteria & study design
DELIVER Trial
In the largest and most inclusive trial of patients with HFpEF and HFmrEF,
dapagliflozin reduced the composite outcome of CV death + WHF
Dapagliflozin was effective in patients with recent HF hospitalization, in those with prior reduced LVEF, with no
attenuation of the effect in the higher LVEF group
“Estos datos apoyan el empleo de iSGLT2 como terapia fundacional en la Insuficiencia Cardíaca, independientemente de la
FEVI”